Pregnancy vaccine shields babies from RSV: major study underway
NCT ID NCT07249320
First seen Jan 04, 2026 · Last updated May 31, 2026 · Updated 26 times
Summary
This study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a serious lung infection. Researchers will compare nearly 40,000 babies born to vaccinated and unvaccinated mothers, tracking infections and hospital visits up to 24 months after birth. The goal is to provide real-world evidence to guide vaccine recommendations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.